Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
On Wednesday, Stifel analysts reiterated their Buy rating for Glaukos Corporation (NYSE: NYSE:GKOS) stock, maintaining a price target of $115, well above the current trading price of $94.12. According to InvestingPro data, analyst consensus remains bullish with targets ranging from $72 to $165. The analysts emphasized a shift in market sentiment regarding the launch trajectory of the iDose product, noting a transition from expectations of rapid growth to a more gradual increase.
The analysts explained that their 15-year discounted cash flow model has been adjusted to reflect a more moderate sales ramp for the iDose in the intermediate term. They highlighted that this adjustment could be beneficial for the stock by reducing the emphasis on short-term performance fluctuations. The company has demonstrated strong revenue growth of 23.92% over the last twelve months, according to InvestingPro data, though they noted that the linear growth pattern might persist into the second and possibly third quarters of 2025 due to seasonal factors.
Despite the adjusted intermediate-term forecast, the analysts remain optimistic about the long-term prospects for iDose. They maintained high peak sales estimates of $1.3 billion in the U.S. and $1.6 billion worldwide, indicating a continued positive outlook for the product. The company maintains a strong financial position with a current ratio of 6.49 and operates with moderate debt levels.
The report also mentioned that reimbursement remains the key factor influencing the growth of iDose sales, according to the analysts’ research. They believe that investors can afford to be patient with the stock, given the gradual launch curve.
Glaukos Corporation is a medical technology company focused on developing and commercializing therapies for the treatment of glaucoma and other eye diseases.
In other recent news, Glaukos Corporation reported its first-quarter 2025 financial results, revealing a revenue of $106.7 million, marking a 25% increase year-over-year. The company also exceeded earnings per share expectations with a reported EPS of -0.22, surpassing the forecast of -0.35. Despite these positive financial indicators, Glaukos’ stock experienced a decline, reflecting investor caution about future growth and regulatory challenges. Stephens, Needham, and JPMorgan analysts have all adjusted their price targets for Glaukos, citing various factors, including market trends and reimbursement challenges, with new targets set at $115 and $100, respectively, while maintaining positive ratings on the stock. Glaukos reaffirmed its full-year revenue guidance of $475-$485 million, with expectations of international glaucoma franchise growth and ongoing product innovation. The company continues to navigate challenges in the U.S. glaucoma market, particularly related to Medicare coverage determinations affecting its primary iStent product. Investors are closely watching for the FDA’s decision on iDose re-treatment by the end of 2025, a potential catalyst for the stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.